Status:
COMPLETED
Platelet Activation by a Collagen Analogue in Hemorrhagic Situations
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Collagen Analog
Platelet Activation
Eligibility:
All Genders
18+ years
Brief Summary
Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular...
Eligibility Criteria
Inclusion
- \- person who has given their non-opposition to inclusion
- adult
- Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.).
- or
- patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or
- patients with antiplatelet therapy or
- patients with thrombocytopenia/thrombopathy
Exclusion
- protected adults (curatorship, guardianship)
- person deprived of their liberty by judicial or administrative decision
- pregnant, parturient or breastfeeding woman
- person unable to express their non-opposition
- platelet transfusion on initial management
Key Trial Info
Start Date :
December 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 11 2023
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT04483245
Start Date
December 7 2021
End Date
April 11 2023
Last Update
July 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21000